Innovent Biologics Inc (6IB) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.029x

Based on the latest financial reports, Innovent Biologics Inc (6IB) has a cash flow conversion efficiency ratio of -0.029x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-311.45 Million ≈ $-364.11 Million USD) by net assets (€10.78 Billion ≈ $12.61 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Innovent Biologics Inc (6IB) net asset quality to measure how much of total assets are equity-financed.

Innovent Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Innovent Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 6IB cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Innovent Biologics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Innovent Biologics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Wipro Limited F:WIOA	0.047x
Sinopac Financial Holdings Co Ltd TW:2890	0.289x
NVR Inc NYSE:NVR	0.111x
CF Industries Holdings Inc NYSE:CF	0.060x
Computershare Ltd AU:CPU	0.153x
JSC National Atomic Company Kazatomprom IL:KAP	0.062x
Ovintiv Inc NYSE:OVV	0.080x
WESCO International Inc NYSE:WCC	0.043x

Annual Cash Flow Conversion Efficiency for Innovent Biologics Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of Innovent Biologics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Innovent Biologics Inc market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€19.36 Billion ≈ $22.63 Billion	€10.00 Billion ≈ $11.69 Billion	0.517x	+426.62%
2024-12-31	€13.12 Billion ≈ $15.34 Billion	€1.29 Billion ≈ $1.50 Billion	0.098x	+731.56%
2023-12-31	€12.53 Billion ≈ $14.65 Billion	€147.81 Million ≈ $172.81 Million	0.012x	+106.60%
2022-12-31	€10.73 Billion ≈ $12.54 Billion	€-1.92 Billion ≈ $-2.24 Billion	-0.179x	+8.77%
2021-12-31	€10.33 Billion ≈ $12.08 Billion	€-2.02 Billion ≈ $-2.37 Billion	-0.196x	-459.30%
2020-12-31	€8.78 Billion ≈ $10.26 Billion	€-307.69 Million ≈ $-359.72 Million	-0.035x	+89.99%
2019-12-31	€4.76 Billion ≈ $5.56 Billion	€-1.66 Billion ≈ $-1.95 Billion	-0.350x	-45.07%
2018-12-31	€4.19 Billion ≈ $4.90 Billion	€-1.01 Billion ≈ $-1.18 Billion	-0.241x	-179.49%
2017-12-31	€-1.62 Billion ≈ $-1.90 Billion	€-492.27 Million ≈ $-575.52 Million	0.303x	-19.89%
2016-12-31	€-958.22 Million ≈ $-1.12 Billion	€-362.99 Million ≈ $-424.38 Million	0.379x	--

About Innovent Biologics Inc

F:6IB Germany Biotechnology

Market Cap

$19.20 Billion

€16.42 Billion EUR

Market Cap Rank

#1481 Global

#332 in Germany

Share Price

€9.47

Change (1 day)

-2.63%

52-Week Range

€7.96 - €11.60

All Time High

€11.80